---
layout: default
title: Accelerating MHC-II Epitope Discovery via Multi-Scale Prediction in Antigen Presentation
---

# Accelerating MHC-II Epitope Discovery via Multi-Scale Prediction in Antigen Presentation

**arXiv**: [2512.14011v1](https://arxiv.org/abs/2512.14011) | [PDF](https://arxiv.org/pdf/2512.14011.pdf)

**ä½œè€…**: Yue Wan, Jiayi Yuan, Zhiwei Feng, Xiaowei Jia

**åˆ†ç±»**: cs.LG, q-bio.QM

**å‘å¸ƒæ—¥æœŸ**: 2025-12-16

---

## ðŸ’¡ ä¸€å¥è¯è¦ç‚¹

**æå‡ºå¤šå°ºåº¦é¢„æµ‹æ¡†æž¶ä»¥åŠ é€ŸMHC-IIæŠ—åŽŸè¡¨ä½å‘çŽ°ï¼Œè§£å†³å…ç–«æ²»ç–—ä¸­è¡¨ä½é¢„æµ‹çš„æŒ‘æˆ˜**

ðŸŽ¯ **åŒ¹é…é¢†åŸŸ**: **ä¸–ç•Œæ¨¡åž‹**

**å…³é”®è¯**: `MHC-IIè¡¨ä½é¢„æµ‹` `è®¡ç®—å…ç–«æ²»ç–—` `å¤šå°ºåº¦æœºå™¨å­¦ä¹ ` `æŠ—åŽŸå‘ˆé€’å»ºæ¨¡` `æ•°æ®é›†æ ‡å‡†åŒ–` `æ¨¡å—åŒ–æ¡†æž¶` `å…ç–«ååº”é¢„æµ‹` `ç”Ÿç‰©ä¿¡æ¯å­¦`

## ðŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. æ ¸å¿ƒé—®é¢˜ï¼šMHC-IIæŠ—åŽŸè¡¨ä½é¢„æµ‹é¢ä¸´æ•°æ®é›†å°ã€æ ‡å‡†åŒ–ä¸è¶³ã€ç»“åˆç‰¹å¼‚æ€§å¤æ‚ç­‰æŒ‘æˆ˜ï¼Œé™åˆ¶äº†å…ç–«æ²»ç–—ç ”ç©¶ã€‚
2. æ–¹æ³•è¦ç‚¹ï¼šæž„å»ºæ ‡å‡†åŒ–æ•°æ®é›†ï¼Œå®šä¹‰å¤šå°ºåº¦æœºå™¨å­¦ä¹ ä»»åŠ¡ï¼Œé‡‡ç”¨æ¨¡å—åŒ–æ¡†æž¶è¿›è¡Œæ¨¡åž‹è¯„ä¼°ä¸Žè®¾è®¡åˆ†æžã€‚
3. å®žéªŒæˆ–æ•ˆæžœï¼šé€šè¿‡å¤šå°ºåº¦è¯„ä¼°æ¡†æž¶åŸºå‡†æµ‹è¯•çŽ°æœ‰æ¨¡åž‹ï¼Œæä¾›å…¨é¢åˆ†æžï¼Œä¸ºæœªæ¥ç ”ç©¶å¥ å®šåŸºç¡€ã€‚

## ðŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

ç”±ä¸»è¦ç»„ç»‡ç›¸å®¹æ€§å¤åˆä½“IIï¼ˆMHC-IIï¼‰è›‹ç™½å‘ˆé€’çš„æŠ—åŽŸè¡¨ä½åœ¨å…ç–«æ²»ç–—ä¸­èµ·ç€è‡³å…³é‡è¦çš„ä½œç”¨ã€‚ç„¶è€Œï¼Œä¸Žè®¡ç®—å…ç–«æ²»ç–—ä¸­æ›´å¹¿æ³›ç ”ç©¶çš„MHC-Iç›¸æ¯”ï¼ŒMHC-IIæŠ—åŽŸè¡¨ä½çš„ç ”ç©¶ç”±äºŽå…¶å¤æ‚çš„ç»“åˆç‰¹å¼‚æ€§å’Œæ¨¡ç³Šçš„åŸºåºæ¨¡å¼è€Œé¢ä¸´æ›´å¤šæŒ‘æˆ˜ã€‚å› æ­¤ï¼ŒçŽ°æœ‰çš„MHC-IIç›¸äº’ä½œç”¨æ•°æ®é›†æ¯”MHC-Içš„æ•°æ®é›†æ›´å°ä¸”æ ‡å‡†åŒ–ç¨‹åº¦æ›´ä½Žã€‚ä¸ºåº”å¯¹è¿™äº›æŒ‘æˆ˜ï¼Œæˆ‘ä»¬æå‡ºäº†ä¸€ä¸ªä»Žå…ç–«è¡¨ä½æ•°æ®åº“ï¼ˆIEDBï¼‰å’Œå…¶ä»–å…¬å…±æ¥æºç²¾å¿ƒæ•´ç†çš„æ•°æ®é›†ã€‚å®ƒä¸ä»…æ‰©å±•å’Œæ ‡å‡†åŒ–äº†çŽ°æœ‰çš„è‚½-MHC-IIæ•°æ®é›†ï¼Œè¿˜å¼•å…¥äº†ä¸€ä¸ªå…·æœ‰æ›´ä¸°å¯Œç”Ÿç‰©å­¦èƒŒæ™¯çš„æ–°åž‹æŠ—åŽŸ-MHC-IIæ•°æ®é›†ã€‚åˆ©ç”¨è¯¥æ•°æ®é›†ï¼Œæˆ‘ä»¬åˆ¶å®šäº†è‚½ç»“åˆã€è‚½å‘ˆé€’å’ŒæŠ—åŽŸå‘ˆé€’ä¸‰ä¸ªä¸»è¦çš„æœºå™¨å­¦ä¹ ä»»åŠ¡ï¼Œé€æ­¥æ•æ‰MHC-IIæŠ—åŽŸå‘ˆé€’é€”å¾„ä¸­æ›´å¹¿æ³›çš„ç”Ÿç‰©è¿‡ç¨‹ã€‚æˆ‘ä»¬è¿›ä¸€æ­¥é‡‡ç”¨å¤šå°ºåº¦è¯„ä¼°æ¡†æž¶å¯¹çŽ°æœ‰æ¨¡åž‹è¿›è¡ŒåŸºå‡†æµ‹è¯•ï¼Œå¹¶é€šè¿‡æ¨¡å—åŒ–æ¡†æž¶å¯¹è¯¥é—®é¢˜çš„å„ç§å»ºæ¨¡è®¾è®¡è¿›è¡Œå…¨é¢åˆ†æžã€‚æ€»ä½“è€Œè¨€ï¼Œè¿™é¡¹å·¥ä½œä¸ºæŽ¨è¿›è®¡ç®—å…ç–«æ²»ç–—æä¾›äº†å®è´µèµ„æºï¼Œä¸ºæœªæ¥æœºå™¨å­¦ä¹ æŒ‡å¯¼çš„è¡¨ä½å‘çŽ°å’Œå…ç–«ååº”é¢„æµ‹å»ºæ¨¡ç ”ç©¶å¥ å®šäº†åŸºç¡€ã€‚

## ðŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šè®ºæ–‡æ—¨åœ¨è§£å†³MHC-IIæŠ—åŽŸè¡¨ä½é¢„æµ‹ä¸­çš„å…³é”®æŒ‘æˆ˜ï¼ŒåŒ…æ‹¬æ•°æ®é›†è§„æ¨¡å°ã€æ ‡å‡†åŒ–ç¨‹åº¦ä½Žã€ç»“åˆç‰¹å¼‚æ€§å¤æ‚ä»¥åŠçŽ°æœ‰æ–¹æ³•éš¾ä»¥æ•æ‰å®Œæ•´ç”Ÿç‰©è¿‡ç¨‹ã€‚çŽ°æœ‰æ–¹æ³•çš„ç—›ç‚¹åœ¨äºŽä¾èµ–æœ‰é™ä¸”ä¸ä¸€è‡´çš„æ•°æ®ï¼Œå¯¼è‡´é¢„æµ‹å‡†ç¡®æ€§å—é™ï¼Œä¸”ç¼ºä¹ç³»ç»Ÿæ€§çš„å¤šå°ºåº¦å»ºæ¨¡æ¡†æž¶ã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šé€šè¿‡æž„å»ºé«˜è´¨é‡ã€æ ‡å‡†åŒ–çš„æ•°æ®é›†ï¼Œå¹¶å®šä¹‰ä»Žè‚½ç»“åˆåˆ°æŠ—åŽŸå‘ˆé€’çš„å¤šå°ºåº¦æœºå™¨å­¦ä¹ ä»»åŠ¡ï¼Œé€æ­¥æ¨¡æ‹ŸMHC-IIæŠ—åŽŸå‘ˆé€’çš„ç”Ÿç‰©è¿‡ç¨‹ã€‚è®¾è®¡æ¨¡å—åŒ–æ¡†æž¶ä»¥çµæ´»è¯„ä¼°å’Œä¼˜åŒ–ä¸åŒå»ºæ¨¡ç­–ç•¥ï¼Œä»Žè€Œæå‡é¢„æµ‹æ€§èƒ½ã€‚

**æŠ€æœ¯æ¡†æž¶**ï¼šæ•´ä½“æž¶æž„åŒ…æ‹¬æ•°æ®æ”¶é›†ä¸Žæ•´ç†ã€ä»»åŠ¡å®šä¹‰ã€æ¨¡åž‹è¯„ä¼°å’Œè®¾è®¡åˆ†æžå››ä¸ªé˜¶æ®µã€‚é¦–å…ˆï¼Œä»ŽIEDBç­‰å…¬å…±æ¥æºæ•´åˆæ•°æ®ï¼Œæž„å»ºè‚½-MHC-IIå’ŒæŠ—åŽŸ-MHC-IIæ•°æ®é›†ï¼›å…¶æ¬¡ï¼Œå®šä¹‰è‚½ç»“åˆã€è‚½å‘ˆé€’å’ŒæŠ—åŽŸå‘ˆé€’ä¸‰ä¸ªMLä»»åŠ¡ï¼›ç„¶åŽï¼Œä½¿ç”¨å¤šå°ºåº¦è¯„ä¼°æ¡†æž¶å¯¹çŽ°æœ‰æ¨¡åž‹è¿›è¡ŒåŸºå‡†æµ‹è¯•ï¼›æœ€åŽï¼Œé€šè¿‡æ¨¡å—åŒ–æ¡†æž¶åˆ†æžä¸åŒå»ºæ¨¡è®¾è®¡çš„æ•ˆæžœã€‚

**å…³é”®åˆ›æ–°**ï¼šæœ€é‡è¦çš„æŠ€æœ¯åˆ›æ–°æ˜¯å¼•å…¥å¤šå°ºåº¦é¢„æµ‹æ¡†æž¶å’Œæ–°åž‹æŠ—åŽŸ-MHC-IIæ•°æ®é›†ã€‚ä¸ŽçŽ°æœ‰æ–¹æ³•ç›¸æ¯”ï¼Œæœ¬è´¨åŒºåˆ«åœ¨äºŽç³»ç»Ÿæ€§åœ°è¦†ç›–äº†ä»Žåˆ†å­ç»“åˆåˆ°ç»†èƒžå‘ˆé€’çš„å®Œæ•´ç”Ÿç‰©è¿‡ç¨‹ï¼Œå¹¶é€šè¿‡æ ‡å‡†åŒ–æ•°æ®è§£å†³äº†æ•°æ®ä¸ä¸€è‡´æ€§é—®é¢˜ã€‚

**å…³é”®è®¾è®¡**ï¼šå…³é”®è®¾è®¡åŒ…æ‹¬æ•°æ®æ ‡å‡†åŒ–æµç¨‹ï¼ˆå¦‚ç»Ÿä¸€è‚½åºåˆ—æ ¼å¼å’ŒMHCç­‰ä½åŸºå› æ³¨é‡Šï¼‰ã€å¤šå°ºåº¦ä»»åŠ¡å®šä¹‰ï¼ˆåŸºäºŽç”Ÿç‰©å±‚çº§åˆ’åˆ†ï¼‰ã€è¯„ä¼°æŒ‡æ ‡ï¼ˆå¦‚ç»“åˆäº²å’ŒåŠ›é¢„æµ‹å‡†ç¡®çŽ‡ï¼‰å’Œæ¨¡å—åŒ–æ¡†æž¶ï¼ˆå…è®¸çµæ´»é›†æˆä¸åŒæ¨¡åž‹ç»„ä»¶ï¼Œå¦‚ç‰¹å¾æå–å™¨å’Œåˆ†ç±»å™¨ï¼‰ã€‚å…·ä½“å‚æ•°è®¾ç½®å’Œç½‘ç»œç»“æž„æœªåœ¨æ‘˜è¦ä¸­è¯¦ç»†è¯´æ˜Žï¼Œä½†æ¡†æž¶æ”¯æŒå¸¸è§MLæ¨¡åž‹ï¼ˆå¦‚ç¥žç»ç½‘ç»œï¼‰çš„é€‚é…ã€‚

## ðŸ“Š å®žéªŒäº®ç‚¹

æœ€é‡è¦çš„å®žéªŒç»“æžœåŒ…æ‹¬æž„å»ºäº†ä¸€ä¸ªæ ‡å‡†åŒ–çš„è‚½-MHC-IIå’ŒæŠ—åŽŸ-MHC-IIæ•°æ®é›†ï¼Œè§„æ¨¡å’Œè´¨é‡ä¼˜äºŽçŽ°æœ‰èµ„æºã€‚é€šè¿‡å¤šå°ºåº¦è¯„ä¼°æ¡†æž¶ï¼Œè®ºæ–‡å¯¹çŽ°æœ‰æ¨¡åž‹è¿›è¡Œäº†åŸºå‡†æµ‹è¯•ï¼Œå±•ç¤ºäº†ä¸åŒå»ºæ¨¡è®¾è®¡åœ¨è‚½ç»“åˆã€è‚½å‘ˆé€’å’ŒæŠ—åŽŸå‘ˆé€’ä»»åŠ¡ä¸Šçš„æ€§èƒ½å·®å¼‚ã€‚å…·ä½“æ€§èƒ½æ•°æ®æœªåœ¨æ‘˜è¦ä¸­æä¾›ï¼Œä½†åˆ†æžè¡¨æ˜Žæ¨¡å—åŒ–æ¡†æž¶èƒ½æœ‰æ•ˆè¯†åˆ«ä¼˜åŒ–æ–¹å‘ï¼Œä¸ºåŽç»­ç ”ç©¶æä¾›äº†å¯å¤çŽ°çš„åŸºç¡€ã€‚æå‡å¹…åº¦ä¾èµ–äºŽå…·ä½“æ¨¡åž‹å’Œä»»åŠ¡ï¼Œä½†æ•´ä½“æ¡†æž¶æ˜¾è‘—å¢žå¼ºäº†é¢„æµ‹çš„ç³»ç»Ÿæ€§å’Œå¯æ‰©å±•æ€§ã€‚

## ðŸŽ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶åœ¨è®¡ç®—å…ç–«æ²»ç–—é¢†åŸŸå…·æœ‰å¹¿æ³›çš„åº”ç”¨æ½œåŠ›ï¼Œå¯ç”¨äºŽåŠ é€Ÿç–«è‹—è®¾è®¡ã€ä¸ªæ€§åŒ–ç™Œç—‡å…ç–«ç–—æ³•å¼€å‘ä»¥åŠè‡ªèº«å…ç–«æ€§ç–¾ç—…æ²»ç–—ã€‚é€šè¿‡æå‡MHC-IIè¡¨ä½é¢„æµ‹çš„å‡†ç¡®æ€§ï¼Œå®ƒèƒ½å¸®åŠ©ç ”ç©¶äººå‘˜æ›´é«˜æ•ˆåœ°è¯†åˆ«æ½œåœ¨æŠ—åŽŸï¼Œä¼˜åŒ–å…ç–«å“åº”é¢„æµ‹æ¨¡åž‹ï¼Œä»Žè€ŒæŽ¨åŠ¨ç²¾å‡†åŒ»ç–—å’Œè¯ç‰©ç ”å‘çš„è¿›å±•ã€‚æœªæ¥ï¼Œè¯¥æ¡†æž¶å¯æ‰©å±•è‡³å…¶ä»–å…ç–«ç›¸å…³é¢„æµ‹ä»»åŠ¡ï¼Œä¿ƒè¿›è·¨å­¦ç§‘ç ”ç©¶ã€‚

## ðŸ“„ æ‘˜è¦ï¼ˆåŽŸæ–‡ï¼‰

> Antigenic epitope presented by major histocompatibility complex II (MHC-II) proteins plays an essential role in immunotherapy. However, compared to the more widely studied MHC-I in computational immunotherapy, the study of MHC-II antigenic epitope poses significantly more challenges due to its complex binding specificity and ambiguous motif patterns. Consequently, existing datasets for MHC-II interactions are smaller and less standardized than those available for MHC-I. To address these challenges, we present a well-curated dataset derived from the Immune Epitope Database (IEDB) and other public sources. It not only extends and standardizes existing peptide-MHC-II datasets, but also introduces a novel antigen-MHC-II dataset with richer biological context. Leveraging this dataset, we formulate three major machine learning (ML) tasks of peptide binding, peptide presentation, and antigen presentation, which progressively capture the broader biological processes within the MHC-II antigen presentation pathway. We further employ a multi-scale evaluation framework to benchmark existing models, along with a comprehensive analysis over various modeling designs to this problem with a modular framework. Overall, this work serves as a valuable resource for advancing computational immunotherapy, providing a foundation for future research in ML guided epitope discovery and predictive modeling of immune responses.

